Malaysian Genomics Resource Centre Berhad's (MGRC) wholly owned subsidiary MGRC Healthcare Sdn Bhd (MGRCH) has entered into two separate collaboration agreements for the purpose of establishing strategic partnerships between the parties and to explore the possibility of cooperations for genetic screening services known as "Origene All-in-One Report" including a derivative product known as "Childhood-Onset Disease Profile" for the cell-gene therapies in respective diseases
In a Bursa filing today, the first was expressed as a Strategic Collaboration Agreement (SCA) with Kumpulan Perubatan Penawar Sdn Bhd (KPPSB); and secondly, a SCA with Hospital Penawar Sdn Bhd (HPSB).
The key indicative obligations of the collaborations include MGRCH shall provide consultancy services and technical support for the Project which includes genetic screen-testing services and providing material and literature for the marketing and promotion of the Project by KPPSB and HPSB.
KPPSB and HPSB shall have the distribution rights to provide the Product through their healthcare facilities and shall be providing consultancy services to consumers, and MGRCH, KPPSB and HPSB shall collaborate to explore the cell-gene therapies in childhood-onset disease.
MGRC is a public limited company incorporated in Malaysia and listed on the ACE Market of Bursa Malaysia Securities Berhad, with its principal activities in providing personalised and precision health solutions through genetics, genomics, immunotherapy and biopharmaceutical services as well as an investment holding company.
While, MGRCH is a wholly owned subsidiary of the Company, with its principal activities in supplying healthcare products and services.
KPPSB is a healthcare group offering polyclinic and hospital services related to medical services such as Pharmacy, Psychiatric Specialist Clinic, Occupational Health Services, Dialysis Centre and other services in multiple locations within Johor. HPSB HPSB is a boutique hospital catering to the surrounding community and selected niche markets, offering an extensive array of specialised clinics with more than 20 specialists across a wide range of medical and surgeries disciplines to meet a wide range of unique healthcare requirements.
The Parties are of the view that there are synergistic benefits to be derived for the SCAs through sharing and developing the knowledge and expertise of both parties in relation to the Product, which is subject to the terms and conditions of the SCAs.